<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549 </FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest event reported): February 24 2009</B>

<P style="font-size: 24pt" align="center"><B>QLT INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>British Columbia,
Canada</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-17082</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>N/A</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>887 Great Northern Way, Suite
101, Vancouver, B.C. Canada,<BR></B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>V5T 4T5</B></TD>
 </TR>

 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(604) 707-7000</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>Not
Applicable<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>ITEM 8.01 OTHER EVENTS.</B>

<P style="font-size: 10pt; text-indent: 4%" align="left">On February&nbsp;24,
2009, QLT Inc. reported that the United States Court of Appeals for the First
Circuit (the &#8220;Court of Appeals&#8221;) denied its Petition for Panel
Rehearing and Rehearing En Banc (&#8220;QLT Petition&#8221;) of the
January&nbsp;12, 2009 Court of Appeals decision. The QLT Petition was filed on
January&nbsp;26, 2009. The January&nbsp;12, 2009 Court of Appeals decision
upheld the liability and damages aspect of the 2007 judgment of the United
States District Court for the District of Massachusetts (the &#8220;District
Court&#8221;) in the lawsuit brought against QLT by Massachusetts Eye and Ear
Infirmary (&#8220;MEEI&#8221;) in connection with events related to U.S. patent
No.&nbsp;5,798,349 (the &#8220;&#8217;349 patent&#8221;) and certain of
MEEI&#8217;s research results related to QLT&#8217;s Visudyne&#174;. The
District Court found QLT liable under Massachusetts state law for unfair trade
practices and ordered QLT to pay to MEEI damages equal to 3.01% on past,
present and future worldwide net sales of Visudyne plus interest and certain
legal fees. The QLT Petition asked the Court of Appeals to reconsider its
decision on two grounds which would impact the foreign sales portion of the
damages. The panel of judges of the Court of Appeals that issued the
January&nbsp;12, 2009 decision ruled that the arguments raised by the QLT
Petition would <I>not </I>change the outcome of that decision. The Court of
Appeals further declined to hear the case en banc. QLT is considering options
for further appellate review.

<P style="font-size: 10pt; text-indent: 4%" align="left">The full text of the
press release is attached as Exhibit&nbsp;99.1 to this Current Report on Form
8-K and is incorporated herein by reference.

<P style="font-size: 10pt" align="left"><B>ITEM 9.01 FINANCIAL STATEMENTS &amp;
EXHIBITS</B>

<P style="font-size: 10pt; text-indent: 4%" align="left"><B>c) Exhibits</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top" align="left" style="border-bottom: #000000 1px solid">Exhibit&nbsp;No.</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left" style="border-bottom: #000000 1px solid">Description</TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release of QLT Inc., dated
February&nbsp;24, 2009</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="left">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 4%" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="48%">&nbsp;</TD>
  <TD width="4%">&nbsp;</TD>
  <TD width="48%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->

<TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD valign="top" align="left" colspan="2"><B>QLT INC.</B></TD>
</TR>


 <TR><TD>&nbsp;</TD></TR>

 <TR valign="bottom">
  <TD valign="top">Date: February&nbsp;24, 2009</TD>
  <TD align="left">By: &nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" valign="top" align="left">/s/ <I>Cameron Nelson</I></TD>
 </TR>


 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Name: Cameron Nelson<BR>
Title: Vice President, Finance and Chief Financial Officer</TD>
 </TR>

</TABLE>
</DIV>

<P style="font-size: 10pt" align="left"><BR>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>





<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>EXHIBIT INDEX</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->

<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top" align="left" style="border-bottom: #000000 1px solid">Exhibit&nbsp;No.</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left" style="border-bottom: #000000 1px solid">Description</TD>
 </TR>

 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV></TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release of QLT Inc., dated
February&nbsp;24, 2009</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>


<P style="font-size: 10pt" align="left"><BR>


<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c81696e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 9983}]
{"company-data": {"conformed-name": "QLT INC/BC", "cik": "0000827809", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "A1", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-17082", "film-number": "09633851"}, "business-address": {"street1": "887 GREAT NORTHERN WAY", "street2": "-", "city": "VANCOUVER", "state": "A1", "zip": "V5T 4T5", "phone": "6047077000"}, "mail-address": {"street1": "887 GREAT NORTHERN WAY", "city": "VANCOUVER", "state": "A1", "zip": "V5T 4T5"}, "former-company": [{"former-conformed-name": "QLT PHOTO THERAPEUTICS INC", "date-changed": "19960618"}, {"former-conformed-name": "QUADRA LOGIC TECHNOLOGIES INC", "date-changed": "19941201"}]}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24 2009
QLT INC.
(Exact name of registrant as specified in its charter)
British Columbia,
Canada
000-17082
N/A
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
887 Great Northern Way, Suite
101, Vancouver, B.C. Canada,
V5T 4T5
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(604) 707-7000
Not
Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS.
On February 24,
2009, QLT Inc. reported that the United States Court of Appeals for the First
Circuit (the "Court of Appeals") denied its Petition for Panel
Rehearing and Rehearing En Banc ("QLT Petition") of the
January 12, 2009 Court of Appeals decision. The QLT Petition was filed on
January 26, 2009. The January 12, 2009 Court of Appeals decision
upheld the liability and damages aspect of the 2007 judgment of the United
States District Court for the District of Massachusetts (the "District
Court") in the lawsuit brought against QLT by Massachusetts Eye and Ear
Infirmary ("MEEI") in connection with events related to U.S. patent
No. 5,798,349 (the "'349 patent") and certain of
MEEI's research results related to QLT's Visudyne®. The
District Court found QLT liable under Massachusetts state law for unfair trade
practices and ordered QLT to pay to MEEI damages equal to 3.01% on past,
present and future worldwide net sales of Visudyne plus interest and certain
legal fees. The QLT Petition asked the Court of Appeals to reconsider its
decision on two grounds which would impact the foreign sales portion of the
damages. The panel of judges of the Court of Appeals that issued the
January 12, 2009 decision ruled that the arguments raised by the QLT
Petition would
not
change the outcome of that decision. The Court of
Appeals further declined to hear the case en banc. QLT is considering options
for further appellate review.
The full text of the
press release is attached as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS &
EXHIBITS
c) Exhibits
Exhibit No.
Description
99.1
Press Release of QLT Inc., dated
February 24, 2009
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
QLT INC.
Date: February 24, 2009
By:
/s/
Cameron Nelson
Name: Cameron Nelson
Title: Vice President, Finance and Chief Financial Officer
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release of QLT Inc., dated
February 24, 2009